The –ibs, –abs and Beyond—Immunotherapies for Pediatric Cancer Treatment and What They Mean for Pain and Symptom Management and Patient Prognosis (TH337)

Use of Immunotherapy for pediatric cancer treatment is rapidly increasing. Medications such as blinatumomab, dinutuxumab, tisagenleclucel and others are dramatically changing the field of pediatric Oncology, and it is imperative that Pediatric Palliative Care (PPC) providers understand pain and symptom management needs as well as changes in prognosis for patients undergoing intensive immunotherapy.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research

Related Links:

CONCLUSIONS: Patients are not always aware of the risk of oral cancer. Accurate information should be provided to patients as well as to specialists rather than just dentists as regard as the risk factors for oral cancer, the importance of referral to specialized departments and timing. The use of new technologies should be widespread. PMID: 32489088 [PubMed - indexed for MEDLINE]
Source: Minerva Stomatologica - Category: Dentistry Tags: Minerva Stomatol Source Type: research
Rationale: Pulmonary sarcomatoid carcinoma (PSC) is an uncommon type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to the conventional chemoradiotherapy. To date, the optimal treatment for PSC has not been elucidated. Patient concerns: Three male patients including a 69-year-old smoker (Case 1), a 45-year-old non-smoker (Case 2), and a 69-year-old smoker (Case 3) were admitted because of cough, back pain, and loss of body weight respectively. Diagnoses: Radiographical examinations in these patients showed bulky intrathoracic lesions, which were pathologically diagnosed as PSC staging ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
DiscussionThe E2C2 intervention offers a pragmatic, scalable approach to delivering guideline-based symptom and function management for cancer patients. Since discrete EHR-imbedded algorithms drive defining aspects of the intervention, the approach can be efficiently disseminated and updated by specifying and modifying these centralized EHR algorithms.Trial,NCT03892967. Registered on 25 March 2019.
Source: Trials - Category: Research Source Type: clinical trials
Having trouble viewing this email? View it as a Web page. NIDCR's Summer 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastruc...
Source: NIDCR Science News - Category: Dentistry Source Type: news
To characterize the health effects of incorporated plutonium, many experiments have been conducted using different animal models. These range from (1) applied (tissue uptake/retention determination, decorporation therapy efficacy), (2) fundamental (gene expression, cancer induction), and (3) dosimetry models. In recent years, the use of animals for scientific purposes has become a public concern. The application of the 3Rs - Replace (use of alternative methods or animals not considered capable of experiencing pain, suffering, and distress), Reduce (reduction in animal numbers), and Refine (better animal welfare and minimiz...
Source: Health Physics - Category: Radiology Tags: Papers Source Type: research
PROSTATE cancer symptoms can be difficult to spot during its early stages, but include passing more urine than normal, erectile dysfunction, and having a burning pain when using the loo. The speed of your urine flow may also reveal your risk of the disease. These are the warning signs of prostate cancer in the toilet.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conclusion: This expanded 50-patient cohort of men with extensive prior therapy confirms our earlier report of high response rates, low toxicity, and improved quality of life with 177Lu-PSMA radioligand therapy. On progression, rechallenge 177Lu-PSMA demonstrated higher response rates than other systemic therapies.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
P2X7 is a transmembrane receptor expressed in multiple cell types including neurons, dendritic cells, macrophages, monocytes, B and T cells where it can drive a wide range of physiological responses from pain transduction to immune response. Upon activation by its main ligand, extracellular ATP, P2X7 can form a nonselective channel for cations to enter the cell. Prolonged activation of P2X7, via high levels of extracellular ATP over an extended time period can lead to the formation of a macropore, leading to depolarization of the plasma membrane and ultimately to cell death. Thus, dependent on its activation state, P2X7 ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionOur cases highlight that an accurate patient examination is warranted following these reconstructions as many of them can be misdiagnosed, and a relatively simple surgery can improve the patients ’ limitations.
Source: Oral and Maxillofacial Surgery - Category: ENT & OMF Source Type: research
This study lays the foundations for the design of a novel approach to study the effects of MWA on bone tumors. As consequence, the MWA treatment settings could be optimized in order to maximize the treatment effects of such a promising clinical application, but also customized for the specific tumor and patient.
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Pain | Pain Management | Palliative | Palliative Care | Pediatrics